Skip to main content

Nontuberculous Mycobacterium Infection

2
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

LigaChem Biosciences
LigaChem BiosciencesKorea - Daejeon
1 program
1
DelpazolidPhase 21 trial
Active Trials
NCT06004037Active Not Recruiting20Est. Dec 2026
Oregon Therapeutics
Oregon TherapeuticsFrance - Paris
1 program
1
gNOPhase 22 trials
Active Trials
NCT07590063Not Yet Recruiting50Est. Sep 2026
NCT03748992Completed10Est. Mar 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
LigaChem BiosciencesDelpazolid
Oregon TherapeuticsgNO
Oregon TherapeuticsgNO

Clinical Trials (3)

Total enrollment: 80 patients across 3 trials

Study to Evaluate the Efficacy of Delpazolid as Add-on Therapy in Refractory Mycobacterium Abscessus Complex

Start: Jan 2024Est. completion: Dec 202620 patients
Phase 2Active Not Recruiting

A Proof of Concept Study of Inhaled Nitric Oxide for Adults With Pulmonary Non-Tuberculous Mycobacterial Infection

Start: Jan 2019Est. completion: Mar 202010 patients
Phase 2Completed

Technology Development of Diagnostic Ultrasound System for Obstetric Imaging

Start: May 2026Est. completion: Sep 202650 patients
N/ANot Yet Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.